GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CollPlant Biotechnologies
CollPlant is an Israeli biotech company producing plant-based recombinant human collagen for use in regenerative medicine. Its stock price reflects its unique technology and partnerships with major medical companies.
Share prices of companies in the market segment - Treatment
CollPlant Biotechnologies is an Israeli company that produces plant-based recombinant human collagen for use in regenerative medicine and 3D bioprinting. We've categorized it as a "Treatment" company. The chart below shows the dynamics of the advanced biomaterials sector.
Broad Market Index - GURU.Markets
CollPlant Biotechnologies is an Israeli company that produces recombinant human collagen based on plants for use in regenerative medicine. As a component of the GURU.Markets index, it represents the biotech sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
CLGN - Daily change in the company's share price CollPlant Biotechnologies
For CollPlant Biotechnologies Ltd., a regenerative medicine company, daily volatility reflects sensitivity to partnership news. This metric is an indicator of demand for its plant-based collagen for 3D bioprinting.
Daily change in the price of a set of shares in a market segment - Treatment
CollPlant Biotechnologies Ltd. is a regenerative medicine company. This chart highlights the high volatility of the biotech sector. Comparison with CLGN's performance, with its unique plant-based collagen technology, helps to assess it as an innovative player.
Daily change in the price of a broad market stock, index - GURU.Markets
CollPlant Biotechnologies uses plants to produce human collagen, used in regenerative medicine. This innovative biotech company's shares are responding to new partnerships and research advances. Its history contributes to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CollPlant Biotechnologies
For CollPlant Biotechnologies, the year-over-year performance is a story about its unique technology for producing human collagen from plants. Its market cap growth over the past 12 months reflects its success in partnering with major companies in the aesthetic medicine and 3D organ bioprinting fields, confirming the potential of its platform.
Annual dynamics of market capitalization of the market segment - Treatment
CollPlant Biotechnologies Ltd. is an Israeli regenerative medicine company that produces plant-based human collagen. Its technology has applications in medicine and cosmetology. The chart below shows how the market views its innovative platform and its partnerships with major companies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CollPlant, with its plant-based collagen production technology, is a speculative bet on the future of medicine and cosmetology. Its stock price is not tied to the economy, but rather driven by its technological breakthroughs and partnerships. The chart tells the story of investors' faith that its innovation will become an industry standard.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CollPlant Biotechnologies
CollPlant Biotechnologies produces recombinant human collagen for medical and aesthetic applications. Its monthly growth is driven by licensing agreements and partnerships with major companies in the fields of bioprinting, aesthetics, and regenerative medicine.
Monthly dynamics of market capitalization of the market segment - Treatment
CollPlant Biotechnologies uses a plant-based platform to produce human collagen for use in regenerative medicine and 3D bioprinting. This is a cutting-edge field of biotech. The chart below shows how investors assessed the prospects of unique biotech platforms and their potential for creating new medical products.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CollPlant Biotechnologies uses a plant-based platform to produce human collagen for use in regenerative medicine. This Israeli company's stock performance depends on the success of its unique technology and partnerships with major medical companies.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CollPlant Biotechnologies
CollPlant Biotechnologies uses a unique plant-based platform to produce human collagen for medical applications. Weekly stock performance is volatile and depends on news of partnerships with major companies and progress in clinical trials of its products.
Weekly dynamics of market capitalization of the market segment - Treatment
CollPlant Biotechnologies uses a unique plant-based platform to produce human collagen for medical applications. Its weekly stock price is volatile, driven by news of partnerships with major companies and progress in clinical trials of its products.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of CollPlant, a biotech company, live in a world of their own. Their performance is driven by news of partnerships. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
CLGN - Market capitalization of the company CollPlant Biotechnologies
CollPlant's market capitalization chart tells the story of an Israeli company using genetically engineered tobacco plants to produce human collagen. Its dynamics reflect investors' faith in the potential of this platform for regenerative medicine, from 3D organ bioprinting to aesthetic procedures.
CLGN - Share of the company's market capitalization CollPlant Biotechnologies within the market segment - Treatment
CollPlant Biotechnologies has developed a plant-based technology for producing human collagen, which is used in regenerative medicine and 3D bioprinting. Its market capitalization reflects the breakthrough potential of its platform. The chart below shows how investors view its partnerships and technology applications.
Market capitalization of the market segment - Treatment
CollPlant Biotechnologies has developed a plant-based technology for producing human collagen for use in regenerative medicine. The chart below shows the overall market capitalization of the treatment sector. It reflects the potential of this unique platform for creating implants and bio-inks for 3D-printed organs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Shown here is 3D printing of human tissue. CollPlant Biotechnologies has developed a technology for producing human collagen from plants, which can be used to print organs and tissues. Their line is a bet on the future of regenerative medicine.
Book value capitalization of the company, segment and market as a whole
CLGN - Book value capitalization of the company CollPlant Biotechnologies
CollPlant's foundation is its technology for producing recombinant human collagen from plants, which is used in regenerative medicine and 3D bioprinting. This represents unique biotech capital. The chart shows how the Israeli company is building its scientific and production base to advance its innovative platform.
CLGN - Share of the company's book capitalization CollPlant Biotechnologies within the market segment - Treatment
CollPlant Biotechnologies produces recombinant human collagen for medical applications. Its unique assets are its tobacco-based "biofactories" and processing facilities. The chart shows the company's share of this cutting-edge biotech infrastructure.
Market segment balance sheet capitalization - Treatment
Regenerative medicine, as the BCap_Ges chart for biotech shows, is a capital-intensive niche. CollPlant Biotechnologies, which produces plant-based collagen for medical applications, must invest in sophisticated manufacturing and R&D capabilities.
Book value of all companies included in the broad market index - GURU.Markets
CollPlant Biotechnologies' assets include unique bioreactors that produce human collagen in tobacco plants. Its value reflects the physical scale of this innovative "plant factory," which creates the material base for 3D bioprinting of organs and tissues.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CollPlant Biotechnologies
CollPlant Biotechnologies uses plants to produce human collagen, which is used in medicine and cosmetology. The value lies in this unique "green" technology. The book value is low. The MvsBCap chart will show how much investors believe this platform will become the new standard for collagen production.
Market to book capitalization ratio in a market segment - Treatment
CollPlant Biotechnologies uses a plant-based platform to produce human collagen for regenerative medicine. Its value lies in this unique technology. The chart shows how the market perceives its potential in 3D bioprinting and aesthetic medicine.
Market to book capitalization ratio for the market as a whole
CollPlant Biotechnologies uses a plant-based platform to produce human collagen, which is used in regenerative medicine and 3D bioprinting. Its value lies in this unique technology. The chart shows how investors evaluate breakthrough biotechnologies that could become the basis for creating tissues and organs.
Debts of the company, segment and market as a whole
CLGN - Company debts CollPlant Biotechnologies
CollPlant, a biotech company producing plant-based human collagen for medical applications, is using the capital to scale up production and conduct clinical trials. This chart shows how the company is funding its unique platform, which can be used in 3D organ bioprinting and aesthetic medicine.
Market segment debts - Treatment
CollPlant Biotechnologies uses a plant-based platform to produce recombinant human collagen, which is used in regenerative medicine. Biotechnology requires significant investment in R&D and production scaling. This chart shows how the company funds its unique and innovative technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CollPlant Biotechnologies
CollPlant Biotechnologies uses plant-based technologies to produce human collagen for medical applications. This chart shows how dependent the company is on external funding for its innovative developments. Their high debt reflects their bet that their unique technology will find widespread application in regenerative medicine.
Market segment debt to market segment book capitalization - Treatment
CollPlant Biotechnologies uses its plant-based technology to produce recombinant human collagen for use in regenerative medicine. The chart shows the sector's debt burden, helping to understand how the company finances its unique biotech platform, which has applications ranging from 3D organ bioprinting to aesthetic medicine.
Debt to book value of all companies in the market
CollPlant Biotechnologies uses a plant-based approach to produce human collagen, used in regenerative medicine and 3D bioprinting. This chart, which shows the overall financial outlook, is critical for innovative companies. The availability of capital for R&D and commercialization of such cutting-edge technologies depends on the health of the global biotech market.
P/E of the company, segment and market as a whole
P/E - CollPlant Biotechnologies
This chart of CollPlant Biotechnologies, a company producing collagen from plants for medical purposes, reflects investor confidence in its unique platform. High values indicate expectations for the application of its collagen in 3D organ bioprinting, aesthetic medicine, and tissue regeneration, opening up vast markets.
P/E of the market segment - Treatment
This chart shows the average P/E for the biotech sector, where CollPlant produces collagen. The industry's high valuation reflects a belief in regenerative medicine. This metric provides context for assessing how revolutionary the market considers CollPlant's 3D bioprinting technology.
P/E of the market as a whole
CollPlant Biotechnologies uses its plant-based technology to produce human collagen, which is used in regenerative medicine, 3D organ bioprinting, and aesthetic medicine. This chart shows the biotech sentiment. It helps understand how the market views the potential of this unique platform for creating revolutionary medical products and how its valuation reflects this long-term potential.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CollPlant Biotechnologies
CollPlant Biotechnologies has developed a technology for producing human collagen from plants, which can be used in regenerative medicine and 3D organ bioprinting. This graph demonstrates analysts' belief that this unique technology will find widespread application in the medicine of the future, enabling the company's exponential growth.
%20P%2FE%20CollPlant%20Biotechnologies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CollPlant-Biotechnologies&v=1772597584615 "Chart of the company's future (projected) P/E CollPlant Biotechnologies")
Future (projected) P/E of the market segment - Treatment
CollPlant Biotechnologies has developed a plant-based technology for producing human collagen, which is used in regenerative medicine and 3D organ bioprinting. This chart shows analysts' estimates of its future revenue, reflecting their belief in its unique and ethical platform for creating the medical products of the future.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Treatment&v=1772597584616 "Future (projected) P/E graph of the market segment - Treatment")
Future (projected) P/E of the market as a whole
CollPlant Biotechnologies uses a plant-based platform to produce human collagen for medical applications. This is a breakthrough biotechnology. This chart, reflecting investor risk appetite, demonstrates the market's willingness to fund such innovative platforms. Market optimism is making it easier for CollPlant to attract partners and investment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772597584632 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CollPlant Biotechnologies
CollPlant Biotechnologies uses a plant-based platform to produce human collagen, which is used in regenerative medicine and 3D organ bioprinting. The company's profits depend on partnerships with major medical companies. This chart shows how breakthrough biotechnology is transformed into commercial products that have the potential to transform medicine.
Profit of companies in the market segment - Treatment
CollPlant Biotechnologies has developed a technology for producing human collagen from tobacco plants. This collagen is used in 3D bioprinting of organs and tissues, as well as in aesthetic medicine. This graph reflects the enormous potential in the regenerative medicine sector, where creating building blocks for the human body could revolutionize the field.
Overall market profit
CollPlant Biotechnologies uses a plant-based platform to produce human collagen for use in regenerative medicine. Commercialization of this technology depends on partnerships with major companies. This chart, reflecting their financial health, demonstrates their willingness to invest in innovative platforms.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CollPlant Biotechnologies
CollPlant Biotechnologies uses a plant-based platform to produce human collagen, which is used in regenerative medicine, 3D organ bioprinting, and aesthetic medicine. This chart summarizes analyst forecasts, which are a bet on the success of this unique biotech platform.
%20profit%20of%20the%20company%20CollPlant%20Biotechnologies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CollPlant-Biotechnologies&v=1772597584778 "Graph of future (projected) profit of the company CollPlant Biotechnologies")
Future (predicted) profit of companies in the market segment - Treatment
CollPlant Biotechnologies has developed a unique plant-based technology for producing recombinant human collagen (rhCollagen). This collagen is used in medical aesthetics and regenerative medicine, such as for 3D bioprinting of organs. This graph shows profitability forecasts for the biotech sector, reflecting the potential of such breakthrough biomaterials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Treatment&v=1772597584805 "Graph of future (predicted) profits of companies in a market segment - Treatment")
Future (predicted) profit of the market as a whole
CollPlant Biotechnologies uses a plant-based platform to produce human collagen for use in regenerative medicine. The company's success depends on the implementation of its technology in clinical practice. The corporate profit forecast shown in the graph influences the investment climate in biotech, which determines the funding of such innovations.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772597584818 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CollPlant Biotechnologies
CollPlant Biotechnologies uses a plant-based platform to produce collagen for medical applications. This chart shows the market valuation of its unique technology. Its high valuation reflects the platform's potential in regenerative medicine and 3D tissue bioprinting.
P/S market segment - Treatment
CollPlant Biotechnologies Ltd. has developed a plant-based technology for producing human collagen for use in regenerative medicine. This chart shows the average revenue estimate in the biotech sector. It allows one to estimate the premium investors are willing to pay for CollPlant's innovative platform and its potential for 3D bioprinting of organs and tissues.
P/S of the market as a whole
CollPlant Biotechnologies has developed a technology for producing plant-based human collagen, which is used in 3D bioprinting of tissues and organs, as well as in medical aesthetics. Their technology is the building block for the medicine of the future. This chart, showing the valuation of companies by actual revenue, highlights the high expectations of investors for breakthrough biotech platforms.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CollPlant Biotechnologies
CollPlant Biotechnologies uses a plant-based platform to produce recombinant human collagen, which is used in regenerative medicine and 3D organ bioprinting. This chart reflects investors' confidence in this unique technology. The valuation is based on future revenue from partnerships with major medical companies.
%20P%2FS%20CollPlant%20Biotechnologies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CollPlant-Biotechnologies&v=1772597584873 "The graph of the company's future (projected) P/S CollPlant Biotechnologies")
Future (projected) P/S of the market segment - Treatment
CollPlant Biotechnologies has developed a plant-based technology for producing human collagen, which is used in 3D bioprinting of tissues and organs, as well as in medical aesthetics. This chart shows how investors value this breakthrough regenerative technology compared to the biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Treatment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Treatment&v=1772597584877 "Future (projected) P/S market segment graph - Treatment")
Future (projected) P/S of the market as a whole
CollPlant Biotechnologies has developed a technology for producing plant-based human collagen, which is used in regenerative medicine. This development, reflecting the market's willingness to invest in breakthrough biotech platforms, is important to CollPlant. Market optimism is helping attract partners and funding to implement this unique technology in medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772597584898 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CollPlant Biotechnologies
CollPlant Biotechnologies has developed a technology for producing recombinant human collagen (rhCollagen) from plants, which is used in medical aesthetics and regenerative medicine. This chart shows revenue from sales of this collagen and partnerships with other companies. It reflects the commercialization of this unique biotech platform.
Sales of companies in the market segment - Treatment
CollPlant Biotechnologies develops and manufactures innovative regenerative medicine products based on its plant-based recombinant human collagen (rhCollagen) technology. The company's business can be divided into revenue from direct sales of its products and revenue from collaborations and licensing. This chart shows revenue from one of these areas.
Overall market sales
CollPlant Biotechnologies uses plant-based technologies to produce human collagen, which is used in regenerative medicine, such as 3D bioprinting of organs. The company is at the forefront of science. Its success could revolutionize medicine and depends on scientific breakthroughs, not the current economic situation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CollPlant Biotechnologies
CollPlant Biotechnologies has developed a technology for producing recombinant human collagen (rhCollagen) from plants, which is used in medical aesthetics and regenerative medicine. Its future sales forecast depends on the success of its products and partnerships with major companies in these fields.
%20sales%20of%20the%20company%20CollPlant%20Biotechnologies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CollPlant-Biotechnologies&v=1772597584924 "Schedule of future (projected) sales of the company CollPlant Biotechnologies")
Future (projected) sales of companies in the market segment - Treatment
CollPlant Biotechnologies has developed a plant-based technology for producing human collagen for use in regenerative medicine. This graph reflects expectations for the entire medical technology sector. It helps assess the growth of the organ and tissue bioprinting market and the demand analysts predict for innovative biomaterials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Treatment&v=1772597584940 "Schedule of future (projected) sales of companies in the market segment - Treatment")
Future (projected) sales of the market as a whole
CollPlant Biotechnologies uses a plant-based approach to produce human collagen for medical applications. Demand for its technology depends on activity in the regenerative medicine sector. This graph of overall sales forecasts reflects the economic confidence driving investment in this cutting-edge field.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772597584976 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CollPlant Biotechnologies
CollPlant Biotechnologies has developed a unique technology for producing human collagen from tobacco plants for use in regenerative medicine and 3D organ bioprinting. This chart reflects its financial trajectory, where revenue from partnerships and technology licensing is balanced against high R&D expenditures.
Market segment marginality - Treatment
CollPlant Biotechnologies uses a plant-based platform to produce human collagen, which is used in regenerative medicine and 3D bioprinting. The effectiveness of their technology lies in its potential to create safe and scalable products. The graph shows their operating costs for commercializing this unique platform.
Market marginality as a whole
CollPlant Biotechnologies has developed a plant-based technology for producing recombinant human collagen. This collagen can be used in medical aesthetics and regenerative medicine. This graph shows the profitability of mature businesses, while CLGN's value is determined by the potential of its unique and safe collagen production platform.
Employees in the company, segment and market as a whole
Number of employees in the company CollPlant Biotechnologies
CollPlant Biotechnologies uses genetically modified tobacco plants to produce human collagen. This graph shows a unique team of scientists and agronomists. The size of this team reflects the scale of their innovative production platform, which offers an alternative to animal-based collagen sources.
Share of the company's employees CollPlant Biotechnologies within the market segment - Treatment
CollPlant Biotechnologies has developed a unique technology for producing human collagen from tobacco plants. This collagen is used in 3D bioprinting of organs and for medical purposes. This figure reflects the company's extensive expertise in the cutting-edge fields of regenerative medicine and bioengineering.
Number of employees in the market segment - Treatment
CollPlant Biotechnologies has developed a plant-based technology for producing human collagen for use in regenerative medicine and 3D bioprinting. This chart reflects employment in the medical and biotechnology sectors. The growing number of tissue engineering specialists indicates breakthroughs in the creation of artificial organs and tissues, where CollPlant collagen is a key building block.
Number of employees in the market as a whole
CollPlant Biotechnologies produces recombinant human collagen for medical applications. Its growth is driven by the trend toward regenerative medicine and partnerships with major companies. This chart shows the overall picture, but for CollPlant, proving the benefits of its platform is more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CollPlant Biotechnologies (CLGN)
CollPlant Biotechnologies Ltd. uses plants to produce human collagen for medical and cosmetic applications. This is a unique biotech platform. The high market capitalization per employee in this chart reflects the value of this patented technology, not the scale of current production.
%20of%20the%20company%20CollPlant%20Biotechnologies%20(CLGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CollPlant-Biotechnologies-CLGN&v=1772597585169 "Chart of market capitalization per employee (in thousands of dollars) of the company CollPlant Biotechnologies (CLGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Treatment
CollPlant Biotechnologies uses its proprietary plant-based technology to produce recombinant human collagen for medical applications. In regenerative medicine, this indicator reflects how the market perceives the uniqueness and potential of their production platform. It is a measure of the value of their "green" biotechnology.
%20by%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Treatment&v=1772597585206 "Market capitalization per employee (in thousands of dollars) by market segment - Treatment")
Market capitalization per employee (in thousands of dollars) for the overall market
CollPlant Biotechnologies has developed a technology for producing plant-based human collagen, which can be used in 3D bioprinting of organs and tissues. This is a futuristic and breakthrough technology. The graph demonstrates the enormous potential the market sees in this unique scientific platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772597585407 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CollPlant Biotechnologies (CLGN)
CollPlant Biotechnologies is an Israeli company that uses genetically engineered tobacco plants to produce human collagen (rhCollagen). This collagen is used in medical aesthetics (fillers) and 3D organ bioprinting. This graph shows how close the company is to commercializing its unique R&D platform, transforming agricultural technologies into high-margin medical products.
%20Chart%20CollPlant%20Biotechnologies%20(CLGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CollPlant-Biotechnologies-CLGN&v=1772597585520 "Company Profit Per Employee (in thousands of dollars) Chart CollPlant Biotechnologies (CLGN)")
Profit per employee (in thousands of dollars) in the market segment - Treatment
CollPlant Biotechnologies has developed a technology based on recombinant human collagen produced in plants for use in regenerative medicine and 3D bioprinting. Their business relies on their scientific team. This chart shows how productive their innovative platform is in creating value compared to other biotech companies.
%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Treatment&v=1772597585535 "Chart of profit per employee (in thousands of dollars) in the market segment - Treatment")
Profit per employee (in thousands of dollars) for the market as a whole
CollPlant (CLGN) is a biotech company producing recombinant collagen (rhCollagen) from tobacco for medical and aesthetic applications. This R&D platform reflects the success of their small team of scientists in commercializing this unique technology through partnerships with major companies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772597585538 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CollPlant Biotechnologies (CLGN)
CollPlant Biotechnologies has developed a plant-based technology for producing human collagen for use in regenerative medicine. This chart shows how the company is monetizing its unique platform through partnerships and supplying raw materials for 3D bioprinting.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CollPlant-Biotechnologies-CLGN&v=1772597585607 "Sales chart per company employee CollPlant Biotechnologies (CLGN)")
Sales per employee in the market segment - Treatment
CollPlant Biotechnologies uses its unique plant platform (tobacco) to produce human collagen (rhCollagen). It is used in 3D bioprinting of organs and in medicine. This chart compares CollPlant's revenue per employee to the industry average, demonstrating the productivity of their unique biotechnology.
Sales per employee for the market as a whole
CollPlant Biotechnologies (CLGN) is an Israeli biotech company. They use genetically engineered tobacco plants to produce human collagen, which is used in 3D bioprinting of organs and in cosmetology. This is their R&D platform. This graph shows the revenue (from partnerships) generated by their unique technology.
Short shares by company, segment and market as a whole
Shares shorted by company CollPlant Biotechnologies (CLGN)
CollPlant Biotechnologies (CLGN) is an Israeli company that uses plants (tobacco) to "grow" human collagen. This collagen is used in 3D bioprinting of organs and in cosmetics. It's revolutionary, but very far from commercialization. This chart shows the number of investors who consider this technology pure speculation.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CollPlant-Biotechnologies-CLGN&v=1772597585996 "Short Shares Chart for the Company CollPlant Biotechnologies (CLGN)")
Shares shorted by market segment - Treatment
CollPlant Biotechnologies is an Israeli company that uses genetically engineered tobacco plants to produce human collagen. This collagen is used in 3D organ bioprinting and cosmetics. This chart shows the odds against the "regenerative medicine" sector, reflecting market skepticism that 3D organ bioprinting will become a reality anytime soon.
Shares shorted by the overall market
CollPlant Biotechnologies uses plant collagen for 3D bioprinting of tissues and organs. This is a breakthrough technology, but one that will likely take a very long time to develop. This chart illustrates the overall market pessimism. Panicked investors are unwilling to fund R&D that could take a decade to produce results. They're selling "dreams" and buying "profits."
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CollPlant Biotechnologies (CLGN)
CollPlant Biotechnologies uses its plant-based platform to produce recombinant human collagen (rhCollagen), used in 3D organ bioprinting and aesthetic medicine. This chart tracks the hype surrounding bioprinting, showing "overheating" (above 70) on partnership news or "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CollPlant-Biotechnologies-CLGN&v=1772597586137 "RSI 14 indicator chart for the company's stock CollPlant Biotechnologies (CLGN)")
RSI 14 Market Segment - Treatment
CollPlant Biotechnologies is an Israeli company that uses genetically engineered tobacco plants to produce human collagen (rhCollagen). This collagen is used in 3D organ bioprinting and aesthetic medicine. This graph tracks the collective sentiment in the regenerative medicine sector. It helps us understand whether CLGN's dynamics are part of the general hype or its unique technology.
RSI 14 for the overall market
CollPlant (CLGN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CLGN (CollPlant Biotechnologies)
CollPlant Biotechnologies is an Israeli company that uses plants (tobacco) to produce human collagen (rhCollagen) for 3D bioprinting of organs and aesthetic medicine. This chart shows the average target price. Analysts' forecasts are based on the potential of this platform and its partnerships (for example, with AbbVie).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CLGN-CollPlant-Biotechnologies&v=1772597586371 "A chart showing analyst consensus forecasts for the expected stock price. CLGN (CollPlant Biotechnologies)")
The difference between the consensus estimate and the actual stock price CLGN (CollPlant Biotechnologies)
CollPlant is an Israeli biotech company that "grows" human collagen in tobacco plants. This collagen is the basis for 3D bioprinted organs and regenerative medicine. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this futuristic platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CLGN-CollPlant-Biotechnologies&v=1772597586379 "A chart showing the difference between the consensus forecast and the actual stock price. CLGN (CollPlant Biotechnologies)")
Analyst consensus forecast for stock prices by market segment - Treatment
CollPlant is an Israeli biotech company that uses tobacco to "grow" human collagen. It is used in 3D bioprinting of organs and in aesthetic medicine. This chart shows analysts' overall expectations for the treatment sector. It reflects whether experts believe in the future of "regenerative" medicine.
Analysts' consensus forecast for the overall market share price
CollPlant is an Israeli biotech company that has developed a unique technology for producing human collagen from plants (tobacco) for 3D bioprinting of tissues and organs. This chart shows the overall "risk appetite" in the market. For CollPlant, a company with a revolutionary but long-term platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CollPlant Biotechnologies
CollPlant Biotechnologies is a vegan collagen company. This Israeli company uses genetically engineered tobacco to grow human collagen, which is then used in bio-inks (for 3D-printed organs) and aesthetic medicine. This graph is a clear indicator of their R&D, reflecting their progress in this futuristic regenerative technology.
AKIMA Market Segment Index - Treatment
CollPlant Biotechnologies (CLGN) is an Israeli regenerative medicine company. They produce recombinant human collagen (rhCollagen) from plants (tobacco) for 3D bioprinting of organs and medical implants. The chart shows the average index for the segment, helping investors assess how this futuristic technology compares to the average.
The AKIM Index for the overall market
CollPlant Biotechnologies is a regenerative medicine company producing collagen from tobacco plants for 3D bioprinting and aesthetics. This chart, reflecting the market average, is just a backdrop. It helps assess how CLGN, a supplier of bioinks for the future of medicine, compares to overall macroeconomic trends.
